Every April 25th, the genetics community marks DNA Day: the anniversary of the 1953 publication in Nature describing the double helix and the 2003 completion of the Human Genome Project. It’s a moment to celebrate and reflect on how far the science has come. This year at 23andMe that celebration is extra special. 23andMe turns 20 in 2026, and the overlap of these two milestones is a testament to what becomes possible when a revolutionary molecule meets a revolutionary idea.
Two decades ago, a small team in California decided that the human genome shouldn’t belong only to researchers in white coats. It should belong to everyone. That bet changed the course of personal genomics, and on this DNA Day it’s worth celebrating just how far that vision has taken us.
The Beginning
When Anne Wojcicki and her co-founders launched 23andMe in 2006, the direct-to-consumer genetics industry simply didn’t exist. Most people weren’t sure why they would ever want to see their own genome, and many experts thought the public couldn’t handle this information. But the 23andMe vision was straightforward: understand the human genome and help build a different kind of healthcare system — one driven by the people and for the people. At the time, that sounded audacious. Looking back, it sounds prescient.
The most consequential idea embedded in 23andMe’s founding wasn’t just that people deserved access to their own genetic data, it was that those same people, at scale, could become active participants in scientific discovery. And the discoveries shouldn’t stop at the journal page. When research yields new findings, those insights should be translated back into reports delivered directly to 23andMe members.
The goal was always for the data to come “full circle” and help the very people who contributed their information. 23andMe created something that had never existed before: a research engine powered by millions of consented participants who wanted to understand themselves and, in doing so, help others.
What Twenty Years Built
The most visible impact of this model has been on individual health. When 23andMe received its first FDA authorization to report health information directly to consumers, it was a landmark moment. It validated the entire premise that people have the right to understand their own biology without a gatekeeper standing in the way. Over the years, additional FDA clearances followed, each one expanding what members could learn about their genetic risk for health conditions, hereditary cancers, and even pharmacogenetic responses to medications.
Those health insights also brought together a community of research participants, who made possible research at a scale that academia and pharma simply couldn’t replicate on their own. By inviting members to opt in to participate in research, 23andMe built one of the world’s largest resources for genetic discovery; and more than 90% of the member base has chosen to opt in and join us in this research. That consent-first, community-powered flywheel has now produced over 300 published studies.
The breadth of what this research community has made possible over twenty years is difficult to compress into any single list, but a few studies stand out:
- In 2016, drawing on data from over 450,000 research participants, 23andMe co-authored what became a landmark study in Nature Genetics that identified 15 genomic regions associated with major depression. This was the first time researchers had cracked the genetics of depression in people of European descent, breaking through years of failed attempts by studies simply too small to find anything.
- That same crowdsourced model powered some of the most important Parkinson’s disease genetics work of the last decade. In collaboration with the Michael J. Fox Foundation, 23andMe has helped build one of the largest Parkinson’s research cohorts in the world, identifying dozens of novel genetic associations that continue to shape drug development today.
- When the COVID-19 pandemic struck, 23andMe mobilized its community rapidly. In less than four months more than a million 23andMe customers consented to participate in this research leading to a study that showed people with type O blood were less likely to contract the virus or test positive after exposure, demonstrating the unique speed at which population-scale genomics can respond to an emerging public health crisis.
- In 2020, our researchers leveraged genetic data from nearly 50,000 people to produce one of the most comprehensive investigations of the transatlantic slave trade ever conducted. We confirmed genetic links between regions in the Americas and areas along the Atlantic coast of Africa, and dated the arrival of specific African populations to different parts of the Western Hemisphere. Three years later, researchers published a study in Science that used ancient DNA to identify nearly 42,000 living Americans with genetic connections to 27 enslaved individuals buried at Maryland’s Catoctin Furnace — including close relatives still living in Maryland, two centuries later. These studies are a reminder that a genetic database is not just a scientific instrument. It can also be a tool for healing.
A Signal of What’s Coming
Our GLP-1 paper, published just weeks ago in Nature, captures what the next twenty years could look like. Our team conducted a large-scale genome-wide association study drawing on data from over 27,000 individuals who had used GLP-1 medications: drugs like semaglutide and tirzepatide that have transformed the management of obesity, but which produce variable results from patient to patient. Just seven months after launching the survey (a remarkably rapid pace for work of this kind), 23andMe researchers found that some of that variability has a genetic explanation. At the same time this work was published we launched a new report and interactive tool related to GLP-1 medications to 23andMe+ Total Health™ members.
This is what precision medicine actually looks like in practice. The vision is that before starting a GLP-1 drug, a patient could receive a personalized profile indicating their likelihood of weight loss and potential side effects, a dramatic shift from the current trial-and-error approach that leaves many patients frustrated and undertreated. The 23andMe Research Institute aims to continue to share the power of our crowdsourced research community to benefit human health.
Looking Forward
The road to get here has not always been straightforward. The company has faced real challenges, recently and throughout its history; those of us who’ve been here through them feel that honestly. But the mission has not changed, it has found a new home in our nonprofit commitment. Our Founder and CEO Anne Wojcicki has said her belief in the company and its future is unwavering, and the commitment to providing access to, and benefit from, genetics remains the north star. The science hasn’t gotten less important. If anything, it’s gotten more urgent.
Anne once said “the future is dripping with possibilities.” Twenty years in, we believe that more than ever. We have discovered enough of the genome to know how much remains a mystery. We have helped enough people to know how many more could be helped. On this DNA Day, seventy-three years after Watson and Crick and twenty years after 23andMe opened our doors, we raise a glass to what’s been achieved, and roll up our sleeves to create a future where breakthroughs belong to all of us.
